Our results, based on human and mouse cell lines, suggest that the MEKi and mtPKCi combination may be effective in a large spectrum of mut KRAS lung cancers regardless of the type of KRAS mutation or additional concurrent alterations in tumor suppressor genes. The gene discussed is KRAS; the disease is lung carcinoma.